Genmab has gone from specialist biotech to front-page story after three cancer drugs cleared key Phase 3 hurdles and the stock price doubled in just three months. That kind of sudden spotlight often leaves some investors overexposed while others are still on the sidelines. This piece looks at how that news ripples through our Innovative Oncology Biotech Stocks screener and reveals three stocks most exposed to the same powerful catalyst.
The stocks highlighted below are just a starter set. The full screen surfaced 16 more oncology focused biotechs with equally compelling stories that are not covered here. To identify, compare, and analyze the highest conviction ideas from this group, head straight to the Innovative Oncology Biotech Stocks screener .
Revolution Medicines (RVMD)
Overview:Revolution Medicines is a clinical-stage precision oncology company developing targeted RAS(ON) therapies for hard-to-treat cancers such as pancreatic and lung.
Market Cap:US$41 billion
Revolution Medicines fits the Innovative Oncology Biotech Stocks theme as a pure play on RAS-driven tumors. Its recent regulatory progress has pushed this specialist into the same late stage conversation investors recently saw ignite interest around Genmab.
"The U.S. FDA approved Rasonque (daraxonrasib) for adults with previously treated metastatic pancreatic adenocarcinoma or those who are not candidates for multiagent chemotherapy, based on the Phase 3 RASolute 302 trial that reported a 60% reduction in risk of death and median overall survival of 13.2 months compared with standard chemotherapy."
One key question for investors is what happens if a relatively quiet variable in Revolution Medicines' RAS(ON) rollout shifts the balance between premium pricing power and long term demand.
If that pricing versus demand trade off matters to you, read the full narrative for Revolution Medicines to see what could be accelerating or stalling the thesis from here.
CG Oncology (CGON)
Overview:CG Oncology is a late stage biopharma business developing cretostimogene, an oncolytic immunotherapy for non muscle invasive bladder cancer.
Operations:CG Oncology currently generates US$6 million in biotechnology revenue, all from patients and activities in the United States.
Market Cap:US$5.7 billion
CG Oncology fits the Innovative Oncology Biotech Stocks theme neatly, with cretostimogene providing investors with exposure to a single, focused bladder cancer program that is already deep into registration quality trials and now moving toward a commercial footing.
"Planned expansion of cretostimogene into intermediate risk and BCG exposed NMIBC, supported by the fully enrolled 364 patient PIVOT-006 trial and the planned randomized Phase 3 in roughly 50,000 BCG exposed patients, could materially widen CG Oncology's treated population and influence future revenue scale."
This raises a question about what happens if a relatively quiet pressure point, relating to how far that commercial build can stretch against fixed costs, shifts even slightly.
If that pressure point matters for your thesis, read the full narrative for CG Oncology to see whether fixed costs are quietly capping or accelerating CG Oncology's upside potential.
BeOne Medicines (ONC)
Overview:BeOne Medicines is a global oncology business that discovers, develops, and sells cancer medicines across blood cancers and solid tumors.
Operations:BeOne Medicines reports US$6.1b in pharmaceutical product revenue, with roughly US$3.3b from the U.S. and US$1.8b from China.
Market Cap:US$42.1b
BeOne Medicines fits the Innovative Oncology Biotech Stocks theme as a rare combination of commercial cancer products and a deep late stage pipeline. This positioning puts it squarely in focus for investors watching how Genmab's recent oncology success resets expectations across the sector.
"The chemo free BRUKINSA plus rituximab regimen in the Phase 3 MANGROVE study, which reduced progression or death risk by 43% versus bendamustine plus rituximab and is heading toward filings in the second half of 2026, can reposition BeOne Medicines more toward continuous, higher value frontline B cell malignancy care that supports longer duration revenue per patient."
The real swing factor is what happens if one quiet constraint on that expanding B cell oncology franchise tightens just as expectations peak.
That quiet constraint is exactly what full narrative for BeOne Medicines unpacks for BeOne Medicines, revealing how the B cell franchise could be accelerating or quietly stalling expectations.
Seeking Fresh Alternatives Before They Fly
Fresh ideas move first. By the time every investor catches the breakout, the clean entry can be gone. Scan these under the radar groups before momentum gets fully priced in and consider them in advance.
-
Spot income workhorses with strong cash support and use the 4 dividend fortresses to see which high yield payers still look under the radar for now.
-
Track the next wave of AI infrastructure momentum by running through the 53 AI infrastructure stocks while these backbone enablers are still priced like second tier suppliers.
-
Hunt for resilient balance sheets that can keep compounding through rough patches and filter for them quickly using the list of solid balance sheet and fundamentals (24 results) .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
